for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Integra Lifesciences Holdings Corp

IART.OQ

Latest Trade

68.50USD

Change

1.35(+2.01%)

Volume

83,652

Today's Range

67.02

 - 

68.55

52 Week Range

42.13

 - 

77.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
67.15
Open
67.65
Volume
83,652
3M AVG Volume
7.38
Today's High
68.55
Today's Low
67.02
52 Week High
77.40
52 Week Low
42.13
Shares Out (MIL)
84.55
Market Cap (MIL)
5,791.63
Forward P/E
23.42
Dividend (Yield %)
--

Next Event

Q2 2021 Integra Lifesciences Holdings Corp Earnings Release

Latest Developments

More

Integra Lifesciences Announces CEO Succession Plan

Integra Lifesciences Reports First Quarter 2021 Financial Results

Integra Lifesciences Reports Q4 And FY20 Financial Results And Provides 2021 Financial Guidance

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Integra Lifesciences Holdings Corp

Integra LifeSciences Holdings Corporation provides regenerative technologies and neurosurgical solutions. The Company offers a portfolio of brands including AmnioExcel, Bactiseal, Certas, Codman, CUSA, DuraGen, DuraSeal, ICP Express, Integra, MediHoney, MicroFrance, PriMatrix, SurgiMend, TCC-EZ, and VersaTru. The Company offers solutions in orthopedics, neurosurgery, and reconstructive and general surgery. The Company operates through two segments: Codman Specialty Surgical segment, and Orthopedics and Tissue Technologies segment. The Codman Specialty Surgical segment includes the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care. The Orthopedics and Tissue Technologies segment includes such offerings as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair products.

Industry

Scientific & Technical Instr.

Contact Info

1100 CAMPUS ROAD

PRINCETON, NJ

08540

United States

+1.609.2750500

https://www.integralife.com/

Executive Leadership

Stuart M. Essig

Independent Chairman of the Board

Peter J. Arduini

President, Chief Executive Officer, Director

Carrie L. Anderson

Chief Financial Officer, Executive Vice President

Glenn G. Coleman

Chief Operating Officer, Executive Vice President

Lisa Evoli

Executive Vice President, Chief Human Resources Officer

Key Stats

2.47 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

1.5K

2019

1.5K

2020

1.4K

2021(E)

1.5K
EPS (USD)

2018

2.420

2019

2.740

2020

2.450

2021(E)

2.925
Price To Earnings (TTM)
34.24
Price To Sales (TTM)
4.20
Price To Book (MRQ)
3.79
Price To Cash Flow (TTM)
20.20
Total Debt To Equity (MRQ)
107.29
LT Debt To Equity (MRQ)
97.10
Return on Investment (TTM)
5.21
Return on Equity (TTM)
4.73

Latest News

Latest News

BRIEF-Integra Lifesciences Holdings Sees Q2 2020 Revenue Of $254 Mln To $256 Mln

* INTEGRA LIFESCIENCES ANNOUNCES PRELIMINARY SECOND QUARTER REVENUE RESULTS; WILL HOST SECOND QUARTER 2020 FINANCIAL RESULTS CONFERENCE CALL ON AUGUST 10, 2020

BRIEF-Integra Lifesciences Announces Positive Clinical Results For Integra Bilayer Wound Matrix

* INTEGRA LIFESCIENCES ANNOUNCES POSITIVE CLINICAL RESULTS FOR INTEGRA® BILAYER WOUND MATRIX (IBWM) Source text for Eikon: Further company coverage:

BRIEF-Integra Lifesciences Reports Q1 Adjusted Earnings Per Share $0.48

* INTEGRA LIFESCIENCES REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Integra Lifesciences Board Approved Temporary Reductions In Base Salaries Of Executive Officers

* INTEGRA LIFESCIENCES HOLDINGS CORP - ON APRIL 16, 2020, BOARD APPROVED TEMPORARY REDUCTIONS IN BASE SALARIES OF COMPANY'S NAMED EXECUTIVE OFFICERS

BRIEF-Integra Lifesciences Sees Q1 2020 Revenue $352 Mln To $354 Mln

* INTEGRA LIFESCIENCES ANNOUNCES PRELIMINARY FIRST QUARTER REVENUE RESULTS AND PROVIDES AN UPDATE ON COVID-19 IMPACT; WILL HOST FIRST QUARTER 2020 FINANCIAL RESULTS CONFERENCE CALL ON MAY 7, 2020

BRIEF-Integra Lifesciences Launches Amnioexcel Plus Placental Allograft Membrane

* INTEGRA LIFESCIENCES LAUNCHES AMNIOEXCEL® PLUS PLACENTAL ALLOGRAFT MEMBRANE Source text for Eikon: Further company coverage:

BRIEF-Integra LifeSciences Reports Q4 Adjusted Earnings Per Share Of $0.68

* INTEGRA LIFESCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES 2020 FINANCIAL GUIDANCE

Integra gets FDA warning letter for Boston plant

Medical device maker Integra Lifesciences Holdings Corp said on Monday it had received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in Boston.

Integra gets FDA warning letter for Boston plant

Medical device maker Integra Lifesciences Holdings Corp said on Monday it had received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in Boston.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up